Crinetics to Showcase Two-Year Paltusotine Data and Phase 2 Atumelnant Results at ENDO 2026
CRNX•Crinetics will present six abstracts at ENDO 2026, featuring two oral PALSONIFY™ presentations with up to two-year safety and efficacy data from PATHFNDR-1 and PATHFNDR-2 studies. Three atumelnant abstracts will disclose Phase 2 congenital adrenal hyperplasia androgen and glucocorticoid reduction results and interim Phase 1b/2a Cushing’s syndrome outcomes.
1. ENDO 2026 Presentation Overview
Crinetics will present six abstracts at the Endocrine Society’s Annual Meeting, ENDO 2026 in Chicago, June 13–16. Presentations include oral and poster sessions covering paltusotine (PALSONIFY™) in acromegaly and atumelnant in congenital adrenal hyperplasia and Cushing’s syndrome.
2. Paltusotine Data Deep Dive
Two oral presentations will feature up to two-year safety and efficacy results from the PATHFNDR-1 and PATHFNDR-2 open-label extension studies evaluating once-daily oral paltusotine in acromegaly patients, alongside posters on real-world biochemical control and combination therapy with cabergoline.
3. Atumelnant Clinical Results
Three atumelnant abstracts include full Phase 2 data in congenital adrenal hyperplasia demonstrating sustained androgen reduction with reduced glucocorticoid dosing, interim Phase 1b/2a findings in ACTH-dependent Cushing’s syndrome, and dose selection modeling for the planned Phase 3 CAH study.
4. Pipeline and Commercial Implications
These data presentations aim to bolster the long-term safety and efficacy profile of PALSONIFY™, support the clinical potential of atumelnant, and underpin upcoming regulatory and commercialization strategies for both therapies in endocrine disorders.
